KRYS
Krystal Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$320.79
−1.42%Price chart
Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21
Key dataOct 21, 2026
Open$324.31
From 52W high−15.17%
Volume77637.00
Market cap$9.49B
P/E (TTM)38.8x
P/S (TTM)21.6x
Div yield—
Key dataOct 21, 2026
Open
$324.31
From 52W high
−15.17%
Volume
77637.00
Market cap
$9.49B
ValuationView details →
P/E (Fwd)
37.2x
EV/EBITDA
39.4x
P/E (TTM)
38.8x
RSI (14)
45.3
MomentumView details →
1D Return
−1.42%
YTD Return
+31.82%
SummaryUpdated Jun 1, 2026
Krystal Biotech, Inc. (NASDAQ:KRYS) is a biotechnology company founded in 2015 and headquartered in Pittsburgh, Pennsylvania. The company specializes in developing redosable gene therapies for rare diseases, with a particular focus on dermatological conditions. Krystal achieved a significant milestone in 2023 when it became the first company to receive FDA approval for a redosable gene therapy with its lead product VYJUVEK (beremagene geperpavec or B-VEC) for treating dystrophic epidermolysis bullosa. The company has successfully transitioned from a clinical-stage biotechnology firm to a profitable commercial enterprise, generating nearly $291 million in revenue in 2024 from VYJUVEK sales alone.
Similar companies
Latest newsMore news →
Krystal Biotech announced positive clinical data for KB113 in three patients with Gorlin syndrome, reporting regression in over 80% of assessed basal cell carcinoma lesions and histologically confirmed clearance of an injected lesion in each patient.6d agoKrystal Biotech reported financial results for the second quarter ended June 30, 2026, with $119.2 million in global VYJUVEK revenue and $1.1 billion in cash and investments.79d ago